FindMyKOL
Clinical trialNCT05038878TerminatedPhase 4Interventional

An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women

NCT05038878 is a phase 4 interventional trial sponsored by Icahn School of Medicine at Mount Sinai. As of 21 Nov 2026, it was terminated. It studies Elagolix in Mild Autonomous Cortisol Excess. The registry lists an enrollment of 4 participants at 1 site in 1 country. The registry lists a start date of 6 Jul 2021 and a primary completion date of 24 Jun 2022.

SponsorIcahn School of Medicine at Mount Sinai →Enrollment4Mild Autonomous Cortisol Excess
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT05038878
FieldValue
Registry IDNCT05038878
StatusTerminated
PhasePhase 4
Study typeInterventional trial
Lead sponsorIcahn School of Medicine at Mount Sinai
Enrollment4
Registered sites1
Countries1
ConditionsMild Autonomous Cortisol Excess
DrugsElagolix
Start6 Jul 2021
Primary completion24 Jun 2022
Study completion24 Jun 2022
Last update posted18 Mar 2025

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this research study is to determine if treatment with Elagolix will improve body weight, waist circumference, muscle strength, cortisol secretion, blood glucose, cholesterol, and bone quality as well as mood and quality of life in a female patient with mild hypercortisolism from adrenal overproduction of cortisol. Many people with adrenal nodules, or non-cancerous growths in the adrenal glands, have mildly elevated cortisol levels. Cortisol is a hormone normally made by the adrenal glands. It is increasingly being recognized that even mild elevations in cortisol levels can negatively impact blood glucose levels, serum cholesterol levels, weight and other metabolic parameters. This can lead to an increase in risk for cardiovascular disease. The study team is trying to determine if the medication Elagolix might be an effective treatment for post-menopausal females with mild hypercortisolism. Elagolix is a medication used to treat a medical condition called endometriosis by decreasing the body's production of sex hormones. Growth of adrenal adenomas is thought to be driven by such sex hormones. Therefore, by decreasing production of these hormones, the study team hopes to treat hypercortisolism caused by adrenal adenomas.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

New York, United States1 site
  • Icahn School of Medicine at Mount Sinai

    New York

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew York: 1 siteNY1MassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Elagolix
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT05038878

Each answer restates registry values shown on this page.

What is NCT05038878?

NCT05038878 is a phase 4 interventional trial sponsored by Icahn School of Medicine at Mount Sinai. It studies Elagolix in Mild Autonomous Cortisol Excess.

Who leads NCT05038878?

The registry names Alice C Levine (principal investigator, Icahn School of Medicine at Mount Sinai) as the overall official.

Where does NCT05038878 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT05038878 study?

The registered drug and biological interventions are Elagolix.

When did NCT05038878 end?

The registry lists a primary completion date of 24 Jun 2022 and a study completion date of 24 Jun 2022. The sponsor last updated the record on 18 Mar 2025.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.